v3.25.2
Stockholders' equity - Summary of Company’s outstanding warrants exercisable for shares of Common Stock (Details)
Jun. 30, 2025
$ / shares
shares
2023 Common Warrants [Member]  
Liability classified warrants (Derivative Warrant Liabilities)  
Number of warrants (in Shares) | shares 2,536,391 [1]
Exercise price | $ / shares $ 3.003 [1]
2023 Pre-Funded Warrants [Member]  
Liability classified warrants (Derivative Warrant Liabilities)  
Number of warrants (in Shares) | shares 1,065,002
Exercise price | $ / shares $ 0.0001
2025 Common Warrants [Member]  
Liability classified warrants (Derivative Warrant Liabilities)  
Number of warrants (in Shares) | shares 4,418,292 [2]
Exercise price | $ / shares $ 3.395 [2]
2025 Pre-Funded Warrants [Member]  
Liability classified warrants (Derivative Warrant Liabilities)  
Number of warrants (in Shares) | shares 1,030,958
Exercise price | $ / shares $ 0.0001
[1] The 2023 Common Warrants will expire on the earlier of (i) the 60th day after the date of the acceptance by the FDA of an NDA for the Company’s product candidate GTx-104 or (ii) September 25, 2028.
[2] The 2025 Common Warrants will expire on the earlier of: (i) the 60th day after the date the FDA approves the NDA for GTx-104 or (ii) September 25, 2028.